Passion for Innovation. Compassion for Patients.™
Daiichi Sankyo Europe GmbH
Dear User,
This website provides you with information only for healthcare professionals. According to the drug
promotion code, we are only able to allow healthcare professionals like physicians and pharmacists to have
full access to our website. To visit our page please login.
European News
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody Collaboration
Daiichi Sankyo
2017-07-19 17:45:01
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research Milestone in Bispecific Antibody
CHMP Issues a Positive Opinion for Daiichi Sankyo’s Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Daiichi Sankyo
2017-07-19 17:45:01
CHMP Issues a Positive Opinion for Daiichi Sankyo’s Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Daiichi Sankyo
2017-07-13 17:45:01
Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center Announce Cancer Research Collaboration
Daiichi Sankyo Announces New Analyses of Once-Daily LIXIANA® (edoxaban) to be Presented at the ISTH 2017 Congress
Daiichi Sankyo
2017-07-10 17:45:01
Daiichi Sankyo Announces New Analyses of Once-Daily LIXIANA® (edoxaban) to be Presented at the ISTH 2017
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban) in Patients with Atrial Fibrillation Undergoing Transcatheter Aortic Valve Implantation
Daiichi Sankyo
2017-05-11 17:45:01
Daiichi Sankyo Initiates ENVISAGE-TAVI AF Study Investigating Once-Daily LIXIANA®▼ (edoxaban) in Patients with
Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients Undergoing Catheter Ablation of Non-valvular Atrial Fibrillation
Daiichi Sankyo
2017-04-03 17:45:01
Daiichi Sankyo Initiates ELIMINATE-AF Study Investigating Once-Daily Lixiana® (edoxaban) in Patients
New analysis demonstrates that insulin-requiring diabetes increases the risk of stroke or systemic embolism in patients with atrial fibrillation
Daiichi Sankyo
2017-01-31 11:45:01
New analysis demonstrates that insulin-requiring diabetes increases the risk of stroke or systemic embolism in
Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA®▼ (edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in NVAF and VTE
Daiichi Sankyo
2017-01-03 13:53:44
Daiichi Sankyo Announces Initiation of Real-World Study in LIXIANA®▼ (edoxaban) Patients Undergoing Diagnostic
Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily LIXIANA®▼ (edoxaban) in Patients with Non-valvular Atrial Fibrillation to be Presented at AHA Scientific Sessions 2016
Daiichi Sankyo
2016-11-08 16:19:27
Daiichi Sankyo Announces New Subgroup Analyses of Once-Daily LIXIANA®▼ (edoxaban) in Patients with
World Stroke Day 2016: Research reveals delayed diagnosis leaves atrial fibrillation patients at major stroke risk
Daiichi Sankyo
2016-10-27 10:32:03
World Stroke Day 2016: Research reveals delayed diagnosis leaves atrial fibrillation patients at major stroke
More Stories
